Cardiovascular events decline for patients using which antidiabetic medication?
Read More »Research Highlights Combination Canagliflozin plus Liraglutide Effects on HBA1c
The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c.
Read More »The Risk of T2D in Children Using Selective Serotonin Reuptake Inhibitors
Is the risk as substantial as was initially reported?
Read More »Diabetes and Subsequent Weight Loss Linked to an Increased Risk of Pancreatic Cancer
The case for expanding screening for pancreatic cancer in those with new onset of diabetes and weight loss.
Read More »The Relationship Between Aerobic Exercise Capacity and Cardiac Dysfunction In T2D
In type 2 diabetes patients, treating diastolic function and myocardial perfusion reserve could improve aerobic exercise capacity and prevent heart failure.
Read More »Possible Link Connecting COVID-19 and New-Onset Diabetes
CoviDIAB Registry will explore why COVID-19 can increase complications in people with pre-existing diabetes, and may also be driving new cases.
Read More »Adding An SGLT-2 Earlier To A Treatment Plan Yields Positive A1c Levels
If dapagliflozin is the second medication prescribed to the patient after the first-line treatments of metformin or sulfonylurea, it has a greater impact.
Read More »Simple Strategies to Prevent Cardiovascular Complications in T2D
Explore three methods to prevent future acute myocardial infarction with diabetes as an underlying agent.
Read More »Heart Rate Variability as a Predictor for the Development of Diabetes
Decreased vagal tone and changes in sympathetic activity may precede the development of cardiometabolic disease or diabetes.
Read More »An Alternative Option for Weight and Glycemia Reduction
Infusion of certain hormones could help in reducing patient weight and glucose levels.
Read More »